You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.


Supplemental Vitamin E May Increase Heart Failure Risk

  • Authors: News Author: Laurie Barclay, MD
    CME Author: Désirée Lie, MD, MSEd
  • CME Released: 3/15/2005; Reviewed and Renewed: 3/15/2006
  • Valid for credit through: 3/15/2007
Start Activity

Target Audience and Goal Statement

This article is intended for primary care physicians, cardiologists, oncologists, and other specialists who counsel patients on vitamin E supplementation.

The goal of this activity is to provide the latest medical news to physicians and other healthcare professionals in order to enhance patient care.

Upon completion of this activity, participants will be able to:

  • Describe the basis for using vitamin E for cancer and cardiovascular disease prevention.
  • Compare the effect of vitamin E supplementation vs placebo on cancer and cardiovascular outcomes.


As an organization accredited by the ACCME, Medscape requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as "financial relationships in any amount, occurring within the past 12 months," that could create a conflict of interest.

Medscape encourages Authors to identify investigational products or off-label uses of products regulated by the U.S. Food and Drug Administration, at first mention and where appropriate in the content.


  • Laurie Barclay, MD

    Laurie Barclay is a freelance reviewer and writer for Medscape.


    Disclosure: Laurie Barclay, MD, has disclosed no relevant financial relationships.


  • Gary Vogin, MD

    Senior Medical Editor, Medscape


    Disclosure: Gary Vogin, MD, has disclosed no relevant financial relationships.

CME Author(s)

  • Désirée Lie, MD, MSEd

    Clinical Professor of Family Medicine; Director, Division of Faculty Development, University of California, Irvine School of Medicine, Irvine, California


    Disclosure: Désirée Lie, MD, MSEd, has disclosed no relevant financial relationships.

Accreditation Statements

    For Physicians

  • Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Medscape designates this educational activity for 0.25 category 1 credit(s) toward the AMA Physician's Recognition Award. Each physician should claim only those credits that reflect the time he/she actually spent in the activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. Medscape encourages you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 5 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.


Supplemental Vitamin E May Increase Heart Failure Risk

Authors: News Author: Laurie Barclay, MD CME Author: Désirée Lie, MD, MSEdFaculty and Disclosures

CME Released: 3/15/2005; Reviewed and Renewed: 3/15/2006

Valid for credit through: 3/15/2007


March 15, 2005 —Supplemental vitamin E does not reduce the risk of cancer of major cardiovascular events but does increase the risk of heart failure, according to the results of the Heart Outcomes Prevention Evaluation — The Ongoing Outcomes (HOPE-TOO) trial, an extension of the randomized Heart Outcomes Prevention Evaluation (HOPE) trial, published in the March 16 issue of JAMA.

"Experimental and epidemiological data suggest that vitamin E supplementation may prevent cancer and cardiovascular events," write Eva Lonn, MD, MSc, from McMaster University in Hamilton, Ontario, Canada, and colleagues. "Clinical trials have generally failed to confirm benefits, possibly due to their relatively short duration."

The initial double-blind HOPE trial, conducted between Dec. 21, 1993, and April 15, 1999, enrolled patients at least 55 years old with vascular disease or diabetes mellitus. The trial was extended (HOPE-TOO) between April 16, 1999, and May 26, 2003. Of the initial 267 HOPE centers that had enrolled 9,541 patients, 174 centers enrolling 7,030 patients participated in the HOPE-TOO trial. Of these 7,030 patients, 916 (13.0%) had died by the beginning of the extension, 1,382 (19.66%) refused to participate, 3,994 (56.81%) continued to take the study intervention (natural source vitamin E, 400 IU, daily or matching placebo), and 738 (10.5%) agreed to passive follow-up. Median duration of follow-up was seven years.

Primary outcome measures were cancer incidence, cancer deaths, and major cardiovascular events (myocardial infarction [MI], stroke, and cardiovascular death), and secondary outcome measures were heart failure, unstable angina, and revascularizations.

The primary analysis revealed no significant differences between groups for all HOPE patients. Cancer incidence was 552 patients (11.6%) in the vitamin E group vs 586 (12.3%) in the placebo group (relative risk [RR], 0.94; 95% confidence interval [CI], 0.84-1.06; P =.30) For cancer deaths, incidence was 156 (3.3%) vs 178 (3.7%), respectively (RR, 0.88; 95% CI, 0.71-1.09; P = .24), and for major cardiovascular events, incidence was 1,022 (21.5%) vs 985 (20.6%), respectively (RR, 1.04; 95% CI, 0.96-1.14; P = .34).

Risk of heart failure was higher in the vitamin E group (RR, 1.13; 95% CI, 1.01-1.26; P = .03), as was hospitalization for heart failure (RR, 1.21; 95% CI, 1.00-1.47; P = .045). For patients enrolled at the centers participating in HOPE-TOO, there were no differences in cancer incidence, cancer deaths, and major cardiovascular events, but rates of heart failure and hospitalizations for heart failure were higher in the vitamin E group.

Limitations of this study include reported cancers not adjudicated in the initial HOPE trial, and possible bias related to not all eligible centers and patients continuing in the study extension. The authors note that the adverse effect of vitamin E was unexpected and unconfirmed by other trials, but that their data were internally consistent. They therefore recommend a meta-analysis of heart failure events in all completed large vitamin E trials.

"In patients with vascular disease or diabetes mellitus, long-term vitamin E supplementation does not prevent cancer or major cardiovascular events and may increase the risk for heart failure," the authors write. "In conjunction with its lack of efficacy, the potential for harm suggested by our findings strongly supports the view that vitamin E supplements should not be used in patients with vascular disease or diabetes mellitus.... Our findings emphasize the need to thoroughly evaluate all vitamins, other natural products, and complementary medicines in appropriately designed trials before they are widely used for presumed health benefits."

The Medical Research Council of Canada, Hoechst-Marion Roussel, AstraZeneca, King Pharmaceuticals, Natural Source Vitamin E Association and Negma, and the Heart and Stroke Foundation of Ontario funded the HOPE trial. Aventis, King Pharmaceuticals, and the Natural Source Vitamin E Association funded the HOPE trial extension (HOPE-TOO). One author reports various financial arrangements with the British Heart Foundation, U.K. Medical Research of Canada, Ontario Heart and Stroke Foundation, AstraZeneca, Aventis, Boehringer-Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Monarch, Merck Sharpe & Dohme, Natural Source Vitamin E Association, Roche, Abbott, Bayer, Boehringer Mannheim, Genentech, Knoll, Menarini, Novartis, Organon, Pfizer, Pharmacia, Sanofi, Schering, and Servier.

In an accompanying editorial, B. Greg Brown, MD, PhD, from the University of Washington School of Medicine, and John Crowley, PhD, from the University of Washington School of Public Health and Community Medicine in Seattle, also emphasize the importance of controlled clinical trials for testing important hypotheses derived from biological mechanisms or from epidemiologic observations.

"The hopes for vitamin E alone or in combination with vitamin C and beta carotene have been diminished by a compelling body of clinical trial evidence, and by certain adverse effects with plausible biological explanation," Drs. Brown and Crowley write. "These hopes are now confined to modest expectations for specific disorders and there are concerns about adverse effects. While there is solid evidence linking oxidative processes to human disease (as well as to normal biological function), the details of these processes and of proposed therapeutic or preventive interventions appear to need considerable rethinking."

JAMA. 2005;293:1338-1347, 1387-1390

  • Print